find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
59
Clinical Trials
Lymphoma
N/A
Enrolling
nct/study# N/A / RWO-DLBCL-RCHOP
Real world outcomes of patients with limited-stage diffuse large B-cell lymphoma treated with abbreviated R-CHOP immunochemotherapy
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / SALVAGETHERAPY-ALK/ALCL
Impact of Salvage Therapy on Outcomes in Patients with Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma Prior to Autologous or Allogeneic Stem Cell Transplant
Learn More
Lymphoma
Phase I
Enrolling
nct/study# NCT05967416 / SIRP01-1001
Phase 1, Open-Label Study of Autologous SIRPA-low Macrophages (SIRPant-M) a cellular therapeutic product Administered by Intratumoral Injection Alone or in Combination with Focal External-Beam Radiotherapy in Participants with Relapsed or Refractory Non-Hodgkin’s Lymphoma
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / TP53-ALTERED-LBCL
TP53-Altered Aggressive Large B-Cell Lymphoma Outcomes by Treatment Modality: A Multicenter Retrospective Review
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / UPENN-EARLY-STAGE-CHL
Multisite, retrospective chart review of practice patterns and outcomes in patients with early-stage classical HL at different institutions within the United States
Learn More
Lymphoma
N/A
Enrolling
nct/study# N/A / NOVELSALVAGETHERAPY-R/R-PMB
Impact of novel salvage regimens in patients with relapsed/refractory primary mediastinal B-cell lymphoma prior to autologous stem cell transplant
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.